Regulation of EBV Latency by Purine Metabolism and Signaling
通过嘌呤代谢和信号传导调节 EBV 潜伏期
基本信息
- 批准号:10407656
- 负责人:
- 金额:$ 45.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-19 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqATRX geneAdenineAdenosineAdenosine KinaseAnabolismB Cell ProliferationB lymphocyte immortalizationB-LymphocytesCellsCellular biologyChIP-seqChromatinChromatin ModelingChromosomesComplexDAXX geneDNA BindingDataDeaminaseEBV-associated diseaseEnzymesEpigenetic ProcessEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensEpstein-Barr Virus latencyEventG-Protein-Coupled ReceptorsGene ExpressionGenesGenomeHistone H3Human Herpesvirus 4Human Herpesvirus 8ImmuneImmune signalingInflammatoryLinkLymphomagenesisLytic VirusMalignant NeoplasmsMass Spectrum AnalysisMetabolicMetabolic ControlMetabolismMolecular ChaperonesNuclearPathway interactionsPlayPrimary InfectionProcessProteinsPurinesPurinoceptorRegulationRoleSignal TransductionTestingTherapeutic InterventionTranscriptional ActivationTranscriptional RegulationViralViral GenesViral PhysiologyVirusVirus DiseasesVirus Latencycell transformationgammaherpesvirushelicaseinhibitormetabolomicsmouse modelnew therapeutic targetnovelpurine metabolismselective expressiontranscriptional reprogrammingtranscriptome sequencingtumortumorigenesisvirus related cancer
项目摘要
Epstein-Barr Virus (EBV) reprograms host cell gene expression and metabolism during the establishment of latency and the immortalization of B-lymphocytes. The regulatory mechanisms coordinating this reprogramming with EBV latency reflect important events in viral oncogenesis, yet remain poorly understood. We have found that key viral regulators of EBV latency, including the major tegument protein BNRF1 and the EBV Nuclear Antigen EBNA1 coordinate key aspects of purine metabolism during establishment of latency and immortalization of primary B-cells. In this R01, we focus on how EBV reprograms purine metabolic gene expression, and how purine metabolites contribute directly to EBV tumorigenesis. One clue to this coordinate regulation is provided by the viral-encoded tegument protein BNRF1 that shares extensive structural similarity to the purine biosynthetic enzyme FGARAT (also called PFAS) and functions in viral chromatin assembly during primary infection. Orthologues of BNRF1 are found in all gamma herpesviruses, including KSHV ORF75, and share the common function of disarming components of the PML-nuclear body (PML-NB) and its anti-viral functions. We have previously shown that BNRF1 interacts with the histone H3.3 chaperone DAXX and displaces its interaction with the ATP-dependent SNF2-like helicase ATRX to enable selective expression of latency-specific viral genes during primary infection. However, it has not yet been shown how the viral FGARAT homology domain is linked to cellular purine biosynthesis and/or signaling. Using metabolomics mass spectrometry, we provide new preliminary data indicating that the purine biosynthetic pathway is among the most significantly perturbed by EBV during B-cell immortalization. Integrating gene expression (RNA-Seq), chromatin accessibility (ATAC-Seq), and EBNA1-DNA binding to host chromosome (ChIP-Seq), we identified cellular metabolic genes, including adenine deaminase (ADA), adenosine kinase 4 (AK4), and purinergic receptors P2RY8 and P2RX5 as direct targets of EBNA1 transcriptional regulation during EBV immortalization. We now propose to investigate the mechanisms by which EBV senses and reprograms purine metabolism and how purinergic signaling regulates establishment of EBV latency and host cell transformation. We will test the central hypothesis that EBV coordinately regulates cellular purine metabolism with viral and cellular gene expression during the B-cell immortalization process, and that purinergic signaling is critical for viral latency and oncogenesis. Specifically, we will investigate how EBV regulates expression of purine metabolic genes during primary infection (Aim 1), elucidate how purine metabolism impacts the establishment of EBV latency (Aim 2), and investigate the role of purine metabolism and signaling in B-cell immortalization, immune signaling, and EBV-induced tumorigenesis (Aim 3). These studies will advance our understanding of basic mechanisms coordinating gene expression with metabolism and identify new targets for therapeutic intervention in viral latency and viral-associated cancers.
EB病毒(Epstein-Barr Virus,EBV)在B淋巴细胞潜伏期的建立和永生化过程中,对宿主细胞的基因表达和代谢进行了重新编程。协调这种重编程与EBV潜伏期的调节机制反映了病毒致癌中的重要事件,但仍知之甚少。我们发现,EBV潜伏期的关键病毒调节因子,包括主要的被膜蛋白BNRF1和EBV核抗原EBNA1,在建立潜伏期和原代B细胞永生化的过程中协调嘌呤代谢的关键方面。在这本R01中,我们重点研究EBV如何重新编程嘌呤代谢基因的表达,以及嘌呤代谢产物如何直接促进EBV肿瘤的发生。病毒编码的被膜蛋白BNRF1提供了这种协调调控的线索之一,它在结构上与嘌呤生物合成酶FGARAT(也称为PFAS)有广泛的相似性,并在初次感染期间参与病毒染色质的组装。BNRF1的同源基因存在于包括KSHV ORF75在内的所有伽玛疱疹病毒中,它们具有解除PML核体成分的共同功能(PML-NB)及其抗病毒功能。我们先前已经证明BNRF1与组蛋白H3.3伴侣DAXX相互作用,并取代其与ATP依赖的SNF2样解旋酶ATRX的相互作用,从而使潜伏期特异性病毒基因在初次感染期间能够选择性表达。然而,目前还没有研究表明病毒的FGARAT同源结构域如何与细胞嘌呤的生物合成和/或信号转导相联系。利用代谢组学质谱仪,我们提供了新的初步数据,表明在B细胞永生化过程中,嘌呤生物合成途径是受EBV干扰最明显的途径之一。结合基因表达(RNA-Seq)、染色质可及性(ATAC-Seq)和EBNA1-DNA与宿主染色体的结合(ChIP-Seq),我们确定了细胞代谢基因,包括腺嘌呤脱氨酶(ADA)、腺苷激酶4(AK4)和嘌呤能受体P2RY8和P2RX5,它们是EBNA1在EBV永生化过程中转录调控的直接靶点。我们现在建议研究EBV感知和重新编程嘌呤代谢的机制,以及嘌呤能信号如何调节EBV潜伏期的建立和宿主细胞的转化。我们将验证中心假设,即EBV在B细胞永生化过程中协调调节细胞嘌呤代谢与病毒和细胞基因表达,以及嘌呤能信号对病毒潜伏期和肿瘤发生至关重要。具体地说,我们将研究EBV如何在初次感染期间调节嘌呤代谢基因的表达(目标1),阐明嘌呤代谢如何影响EBV潜伏期的建立(目标2),并研究嘌呤代谢和信号在B细胞永生化、免疫信号和EBV诱导的肿瘤形成中的作用(目标3)。这些研究将促进我们对基因表达与新陈代谢协调的基本机制的理解,并为病毒潜伏和病毒相关癌症的治疗干预确定新的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL M LIEBERMAN其他文献
PAUL M LIEBERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL M LIEBERMAN', 18)}}的其他基金
Project 4: Regulation of EBV Latency and Oncogenesis by Hypoxia
项目4:缺氧对EBV潜伏期和肿瘤发生的调节
- 批准号:
10714176 - 财政年份:2023
- 资助金额:
$ 45.76万 - 项目类别:
Epigenomic Drivers of EBV Epithelial Cancers
EB 病毒上皮癌的表观基因组驱动因素
- 批准号:
10627690 - 财政年份:2023
- 资助金额:
$ 45.76万 - 项目类别:
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers
针对 EB 病毒上皮癌的表观遗传和代谢控制
- 批准号:
10627689 - 财政年份:2023
- 资助金额:
$ 45.76万 - 项目类别:
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL
EBNA1 抑制剂用于治疗 EBV 阳性 DLBCL
- 批准号:
10719866 - 财政年份:2023
- 资助金额:
$ 45.76万 - 项目类别:
Drugging EBNA1 to Treat EBV-Associated Cancers - Diversity Supplement
使用 EBNA1 药物治疗 EBV 相关癌症 - Diversity Supplement
- 批准号:
10818976 - 财政年份:2021
- 资助金额:
$ 45.76万 - 项目类别:
Drugging EBNA1 to Treat EBV-Associated Cancers
药物 EBNA1 治疗 EBV 相关癌症
- 批准号:
10185459 - 财政年份:2021
- 资助金额:
$ 45.76万 - 项目类别:
Regulation of EBV Latency by Purine Metabolism and Signaling
通过嘌呤代谢和信号传导调节 EBV 潜伏期
- 批准号:
10298045 - 财政年份:2021
- 资助金额:
$ 45.76万 - 项目类别:
相似海外基金
Molecular pathological mechanisms of the brain development disorder using the chromatin-remodeling molecule ATRX gene knockout mouse
染色质重塑分子ATRX基因敲除小鼠脑发育障碍的分子病理机制
- 批准号:
23300147 - 财政年份:2011
- 资助金额:
$ 45.76万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Functional analysis of the Zn finger domain encoded by the ATRX gene whose mutations result in X-linked alpha thalassemia mental retardation(ATR-X) syndrome
ATRX基因编码的锌指结构域的功能分析,其突变导致X连锁α地中海贫血精神发育迟滞(ATR-X)综合征
- 批准号:
18570170 - 财政年份:2006
- 资助金额:
$ 45.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Y CHROMOSOME MODEL FOR THE SEX DETERMINING FUNCTION OF THE HUMAN ATRX GENE
人类 ATRX 基因性别决定功能的 Y 染色体模型
- 批准号:
nhmrc : 148630 - 财政年份:2001
- 资助金额:
$ 45.76万 - 项目类别:
NHMRC Project Grants
Investigation of the role of the ATRX gene in normal mammalian development
ATRX 基因在正常哺乳动物发育中的作用研究
- 批准号:
nhmrc : 987013 - 财政年份:1998
- 资助金额:
$ 45.76万 - 项目类别:
Early Career Fellowships














{{item.name}}会员




